induced-proximity medicine
Very little changed. In June 2023, General Proximity said it was building the next generation of induced-proximity medicines and framed engineered molecular proximity as a way to control biology and widen the set of treatable diseases. By January 7, 2024, the homepage was still saying essentially the same thing: induced proximity is the modality, and this is the hill the company plans to stand on. What stayed stable is the core belief. No visible pivot, no public hedging, no sudden detour into some shinier label. The company continued to present induced-proximity medicine not as a side project or enabling tool, but as the central therapeutic thesis. What changed is mostly the level of detail we can see, which is not much. The 2023 wording is a bit more explicit about the mechanism and ambition; the 2024 snapshot is shorter and more slogan-like. That is a change in presentation, not obviously a change in belief. Evidence is thin because both entries are homepage snapshots, and homepage copy is marketing copy. Useful, yes, but not a full map of internal scientific conviction. Based on what is here, the belief looks highly stable.